Investigating the effect of maraviroc on Microbial Translocation in HIV infected individuals who are receiving antiretroviral therapy: a phase IV, prospective, intervention study

Trial Profile

Investigating the effect of maraviroc on Microbial Translocation in HIV infected individuals who are receiving antiretroviral therapy: a phase IV, prospective, intervention study

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Maraviroc (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms MT-Study
  • Most Recent Events

    • 02 Apr 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
    • 19 Dec 2013 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
    • 04 Dec 2013 Accrual to date is 40% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top